Published in Arch Neurol on May 01, 1990
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord (1991) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis. Neurology (2009) 2.26
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Distinct genetic forms of frontotemporal dementia. Neurology (2008) 2.15
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. Ned Tijdschr Geneeskd (2004) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler (2006) 1.99
Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology (1998) 1.94
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res (2004) 1.90
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology (2010) 1.88
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
Familial aggregation in frontotemporal dementia. Neurology (1998) 1.76
Effect of flow and pressure on pulmonary vessels. A semiquantitative study based on lung biopsies. Circulation (1967) 1.70
The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene (2007) 1.69
Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology (2009) 1.68
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology (2004) 1.65
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 1.63
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol (2009) 1.60
Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain (2001) 1.59
Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain (2005) 1.57
The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis (2006) 1.56
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain (2001) 1.56
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet (1995) 1.53
Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis. Ann Neurol (2001) 1.53
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 1.50
Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am J Pathol (1998) 1.50
Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment. Clin Endocrinol (Oxf) (1998) 1.49
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler (2001) 1.45
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Pregnancy-related primary brain and spinal tumors. Arch Neurol (1987) 1.44
Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol (1996) 1.43
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol (1997) 1.43
Renal allograft rejection and antibodies to epithelial cells. Lancet (1992) 1.42
MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med (2005) 1.42
The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment. J Neurol Neurosurg Psychiatry (2003) 1.41
Primary spinal epidural extraosseous Ewing's sarcoma. Cancer (1991) 1.39
Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol (1999) 1.39
[Cerebrospinal fluid diagnosis using polymerase chain reaction]. Ned Tijdschr Geneeskd (1996) 1.38
Echocardiographic diagnosis of pseudoaneurysm of the left ventricle. Circulation (1975) 1.38
Muscular changes in the guinea pig caused by chronic ascorbic acid deficiency. J Neurol Sci (1991) 1.37
Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res (2007) 1.36
A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun (2006) 1.35
Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci (2000) 1.32
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol (1998) 1.30
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain (2003) 1.29
Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler (2003) 1.28
Autosomal dominant diffuse leukoencephalopathy with neuroaxonal spheroids. Neurology (2000) 1.28
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol (2009) 1.26
Induction of neonatal sodium channel II and III alpha-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur J Neurosci (2001) 1.25
Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis (2007) 1.25
Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol (2004) 1.25
Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. Brain (2001) 1.25
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain (1999) 1.22
Prenatal programming of nephron number and blood pressure. Kidney Int (2007) 1.21
The pulmonary vasculature in complete transpossition of the greatvessels, judged from lung biopsies. Circulation (1968) 1.21
Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience (2011) 1.21
Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol (1999) 1.20
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology (2004) 1.18
Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology (2002) 1.18
Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler (2009) 1.15
Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry (2002) 1.14
Evidence of activated microglia in focal cortical dysplasia. J Neuroimmunol (2006) 1.14
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain (2002) 1.13
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler (2001) 1.13
Frontal presentation in progressive supranuclear palsy. Neurology (2007) 1.12
Multiple sclerosis functional composite: impact of reference population and interpretation of changes. Mult Scler (2002) 1.12
Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett (2003) 1.11
Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis. J Neuroimmunol (1986) 1.11
Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience (2001) 1.11
Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol (2005) 1.10
The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol (1995) 1.10
Ventricular free wall rupture: sudden, subacute, slow, sealed and stabilized varieties. Eur Heart J (1984) 1.10